[Federal Register Volume 87, Number 113 (Monday, June 13, 2022)]
[Notices]
[Pages 35787-35788]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-12655]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2022-N-0686]


Advisory Committee; Science Advisory Board to the National Center 
for Toxicological Research; Renewal

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; renewal of Federal advisory committee.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA or Agency) is announcing 
the renewal of the Science Advisory Board to the National Center for 
Toxicological Research (NCTR) by the Commissioner of Food and Drugs 
(the Commissioner). The Commissioner has determined that it is in the 
public interest to renew the Science Advisory Board to the National 
Center for Toxicological Research for an additional 2 years beyond the 
charter expiration date. The new charter will be in effect until the 
June 2, 2024, expiration date.

DATES: Authority for the Science Advisory Board to the National Center 
for Toxicological Research will expire on June 2, 2024, unless the 
Commissioner formally determines that renewal is in the public 
interest.

FOR FURTHER INFORMATION CONTACT: Donna L. Mendrick, National Center for 
Toxicological Research, Food and Drug Administration, 10903 New 
Hampshire Ave., Bldg. 32, Rm. 2208, Silver Spring, MD 20993-0002, 301-
796-8892, [email protected].

SUPPLEMENTARY INFORMATION: Pursuant to 41 CFR 102-3.65 and approval by 
the Department of Health and Human Services pursuant and by the General 
Services Administration, FDA is announcing the renewal of the Science 
Advisory Board to the National Center for Toxicological Research (the 
Committee). The Committee is a discretionary Federal advisory committee 
established to provide advice to the Commissioner. The Committee 
advises the Commissioner or designee in discharging responsibilities as 
they relate to helping to ensure safe and effective drugs for human use 
and, as required, any other product for which FDA has regulatory 
responsibility.
    The Committee advises the Director, NCTR, in establishing, 
implementing, and evaluating research programs that assist the 
Commissioner in fulfilling his regulatory responsibilities. The 
Committee provides an extra-agency review in ensuring that the research 
programs at NCTR are scientifically sound and pertinent.
    The Committee shall consist of a core of nine voting members 
including the Chair. Members and the Chair are selected by the 
Commissioner or designee from among authorities knowledgeable in the 
fields of toxicological research. Members will be invited to serve for 
overlapping terms of up to 4 years. Almost all non-Federal members of 
this committee serve as Special Government Employees. Federal members 
will be appointed as Regular Government Employees or Ex-Officios. The 
core of voting members may include one technically qualified member, 
selected by the Commissioner or designee, who is identified with 
consumer interests and is recommended by either a consortium of 
consumer-oriented organizations or other interested persons.
    The Commissioner or designee shall have the authority to select 
members of other scientific and technical FDA advisory committees 
(normally not to exceed 10 members) to serve temporarily as voting 
members and to designate consultants to serve temporarily as voting 
members when: (1) expertise is required that is not available among 
current voting standing members of the Committee (when additional 
voting members are added to the Committee to provide needed expertise, 
a quorum will be based on the combined total of regular and added 
members) or (2) to comprise a quorum when, because of unforeseen 
circumstances, a quorum is or will be lacking. Because of the size of 
the Committee and the variety in the types of issues that it will 
consider, FDA may, in connection with a particular committee meeting, 
specify a quorum that is less than a majority of the current voting 
members. The Agency's regulations (21 CFR 14.22(d)) authorize a 
committee charter to specify quorum requirements.
    If functioning as a medical device panel, an additional non-voting 
representative member of consumer interests will be included in 
addition to the voting members.

[[Page 35788]]

    Further information regarding the most recent charter and other 
information can be found at https://www.fda.gov/advisory-committees/toxicological-research-science-advisory-board-national-center-toxicological-research/charter-science-advisory-board-national-center-toxicological-research or by contacting the Designated Federal Officer 
(see FOR FURTHER INFORMATION CONTACT). In light of the fact that no 
change has been made to the committee name or description of duties, no 
amendment will be made to 21 CFR 14.100.
    This notice is issued under the Federal Advisory Committee Act (5 
U.S.C. app.). For general information related to FDA advisory 
committees, please visit us at http://www.fda.gov/AdvisoryCommittees/default.htm.

    Dated: June 3, 2022.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2022-12655 Filed 6-10-22; 8:45 am]
BILLING CODE 4164-01-P